{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:04:49Z","timestamp":1794708289192,"version":"4.9.1"},"reference-count":34,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,26]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The efficacy of and disease control afforded by tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia in chronic phase (CML-CP) have led to increased longevity and thus the continued pursuit of alternative therapies that are efficacious and maximize tolerability. The 24- and 96-week analyses from ASCEMBL demonstrated superior efficacy, safety, and tolerability of asciminib when compared with bosutinib in later-line therapy, thereby meeting the primary and key secondary objectives. With nearly 4 years of follow-up, data from ASCEMBL continued to demonstrate the superior efficacy, safety, and tolerability of asciminib over bosutinib. At week 156, the major molecular response (MMR) rates remained higher with asciminib (33.8%) than with bosutinib (10.5%); the difference in MMR rates between arms, after adjusting for baseline major cytogenetic response, was 23.2% (95% confidence interval, 13.14-33.18; 2-sided P &amp;lt; .001). Asciminib continued to cause fewer grade \u22653 adverse events (AEs; 59.6% vs 68.4%) and fewer AEs that led to treatment discontinuation (8.3% vs 27.6%) than bosutinib. This updated analysis also includes patients who switched to asciminib because of a lack of efficacy with bosutinib. Two of the 25 patients who switched achieved MMR by the end of study, suggesting that earlier incorporation of asciminib, before other TKIs, may improve responses, albeit modestly. These long-term results further solidify asciminib as the therapy of choice for patients with CML-CP who were previously treated with \u22652 previous TKIs. This trial was registered at clinicaltrials.gov as #NCT03106779.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016042","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T14:34:17Z","timestamp":1746628457000},"page":"4248-4259","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2251-4032","authenticated-orcid":false,"given":"Michael J.","family":"Mauro","sequence":"first","affiliation":[{"name":"1Chronic Myeloid Leukemia Program, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-0739","authenticated-orcid":false,"given":"Yosuke","family":"Minami","sequence":"additional","affiliation":[{"name":"2Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0626-0834","authenticated-orcid":false,"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Internal Oncology, Universit\u00e4tsklinikum Jena, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3290-7961","authenticated-orcid":false,"given":"Elza","family":"Lomaia","sequence":"additional","affiliation":[{"name":"4Institute of Oncology and Hematology, Almazov National Medical Research Centre, St Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1784-0375","authenticated-orcid":false,"given":"Sergey","family":"Voloshin","sequence":"additional","affiliation":[{"name":"5Hematology and Bone Marrow Transplantation, Russian Research Institute of Hematology and Transfusiology, St Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Turkina","sequence":"additional","affiliation":[{"name":"6Scientific and Advisory Department of Hemotherapy of Myeloproliferative Disorders, National Medical Research Center for Hematology, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[{"name":"7Hematologic Tumor Medicine Department, Uijeongbu Eulji Medical Center, Uijeongbu, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1710-1794","authenticated-orcid":false,"given":"Jane F.","family":"Apperley","sequence":"additional","affiliation":[{"name":"8Department of Immunology and Inflammation, Centre for Haematology, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-1071","authenticated-orcid":false,"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[{"name":"9Department of Leukemia, Georgia Cancer Center, Augusta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7486-3525","authenticated-orcid":false,"given":"Andre","family":"Abdo","sequence":"additional","affiliation":[{"name":"10Hemato-Oncology Department, Instituto do C\u00e2ncer do Estado de S\u00e3o Paulo, S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5011-192X","authenticated-orcid":false,"given":"Laura Maria","family":"Fogliatto","sequence":"additional","affiliation":[{"name":"11Hematology and Hemotherapy Department, Hospital de Cl\u00ednicas de Porto Alegre, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis Dong Hwan","family":"Kim","sequence":"additional","affiliation":[{"name":"12Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"le Coutre","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0357-5785","authenticated-orcid":false,"given":"Susanne","family":"Saussele","sequence":"additional","affiliation":[{"name":"14Department of Haematology and Oncology, III. Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9993-947X","authenticated-orcid":false,"given":"Mario","family":"Annunziata","sequence":"additional","affiliation":[{"name":"15Division of Hematology, Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[{"name":"16Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute and The University of Adelaide, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8623-1798","authenticated-orcid":false,"given":"Naeem","family":"Chaudhri","sequence":"additional","affiliation":[{"name":"17Hematology, Stem Cell Transplant and Cellular Therapy Section, King Faisal Specialist Hospital & Research Centre, Riyadh, Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4250-4448","authenticated-orcid":false,"given":"Lynette","family":"Chee","sequence":"additional","affiliation":[{"name":"18Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4752-0815","authenticated-orcid":false,"given":"Valentin","family":"Garc\u00eda-Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"19Department of Hematology and Hemotherapy, Servicio de Hematolog\u00eda, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[{"name":"20Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Boquimpani","sequence":"additional","affiliation":[{"name":"21Hematology Department, Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Kapoor","sequence":"additional","affiliation":[{"name":"22Novartis Pharmaceuticals Corporation, East Hanover, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Espurz","sequence":"additional","affiliation":[{"name":"23Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Dhamal","sequence":"additional","affiliation":[{"name":"24Novartis Healthcare Private Limited, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5379-7461","authenticated-orcid":false,"given":"Delphine","family":"Rea","sequence":"additional","affiliation":[{"name":"25DMU H\u00e9matologie, H\u00f4pital Saint-Louis, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"issue":"24","key":"2025082608315833100_bib1","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025082608315833100_bib2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/PPO.0b013e31823dec8d","article-title":"Evolution of therapies for chronic myelogenous leukemia","volume":"17","author":"Santos","year":"2011","journal-title":"Cancer J"},{"issue":"4","key":"2025082608315833100_bib3","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"2025082608315833100_bib4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11899-016-0306-5","article-title":"Quality of life and long-term therapy in patients with chronic myeloid leukemia","volume":"11","author":"Flynn","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"issue":"23","key":"2025082608315833100_bib5","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"2025082608315833100_bib6","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol"},{"issue":"7","key":"2025082608315833100_bib7","first-page":"421","article-title":"The \"hit hard and hit early\" approach to the treatment of chronic myeloid leukemia: implications of the updated National Comprehensive Cancer Network Clinical Practice Guidelines for routine practice","volume":"11","author":"Akard","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"2025082608315833100_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","article-title":"Third-line therapy for chronic myeloid leukemia: current status and future directions","volume":"14","author":"Cortes","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"12","key":"2025082608315833100_bib9","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/ajh.24536","article-title":"Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"2025082608315833100_bib10","doi-asserted-by":"crossref","first-page":"IJH38","DOI":"10.2217\/ijh-2021-0010","article-title":"The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"11","author":"Saydam","year":"2022","journal-title":"Int J Hematol Oncol"},{"key":"2025082608315833100_bib11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/JBM.S129821","article-title":"Bosutinib in chronic myeloid leukemia: patient selection and perspectives","volume":"9","author":"Isfort","year":"2018","journal-title":"J Blood Med"},{"issue":"10","key":"2025082608315833100_bib12","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2025082608315833100_bib13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"2025082608315833100_bib14","author":"Cortes","year":"11-14  2020"},{"key":"2025082608315833100_bib15","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.2147\/PPA.S269355","article-title":"Monitoring and improving adherence to tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a systematic review","volume":"15","author":"Tan","year":"2021","journal-title":"Patient Prefer Adherence"},{"key":"2025082608315833100_bib16","doi-asserted-by":"crossref","first-page":"100968","DOI":"10.1016\/j.blre.2022.100968","article-title":"Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - what to look for when treatment-free remission is not an option","volume":"56","author":"Lipton","year":"2022","journal-title":"Blood Rev"},{"issue":"11","key":"2025082608315833100_bib17","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1185\/03007995.2014.944973","article-title":"Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase","volume":"30","author":"Gu\u00e9rin","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"S2","key":"2025082608315833100_bib18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/HS9.0000000000000200","article-title":"TKI safety","volume":"3","author":"Hjorth-Hansen","year":"2019","journal-title":"Hemasphere"},{"key":"2025082608315833100_bib19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1515\/med-2019-0004","article-title":"Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia","volume":"14","author":"Malkan","year":"2019","journal-title":"Open Med (Wars)"},{"issue":"21","key":"2025082608315833100_bib20","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"R\u00e9a","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2025082608315833100_bib21","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"},{"issue":"S3","key":"2025082608315833100_bib22","doi-asserted-by":"crossref","first-page":"e55133e1","DOI":"10.1097\/01.HS9.0000969648.55133.e1","article-title":"Real-world efficacy profile of asciminib in an Italian, multi-resistant chronic-phase chronic myeloid leukemia (CP-CML) patient population","volume":"7","author":"Breccia","year":"2023","journal-title":"Hemasphere"},{"issue":"6","key":"2025082608315833100_bib23","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"2025082608315833100_bib24","author":"Mauro","year":"9-12  2023"},{"issue":"7","key":"2025082608315833100_bib25","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/s41375-024-02278-8","article-title":"Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after &gt;\/=1 prior tyrosine kinase inhibitor: 2-year follow-up results","volume":"38","author":"Cortes","year":"2024","journal-title":"Leukemia"},{"issue":"20","key":"2025082608315833100_bib26","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","article-title":"The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up","volume":"114","author":"Garg","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2025082608315833100_bib27","doi-asserted-by":"crossref","first-page":"e1376","DOI":"10.1002\/hsr2.1376","article-title":"Chronic myeloid leukemia kinase domain mutations: a retrospective descriptive study on the therapeutic and prognostic significance in patients at King Edward VIII Hospital, KwaZulu-Natal, South Africa","volume":"6","author":"Benjamin","year":"2023","journal-title":"Health Sci Rep"},{"issue":"5","key":"2025082608315833100_bib28","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41375-025-02578-7","article-title":"Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: phase 1 final results","volume":"39","author":"Hochhaus","year":"2025","journal-title":"Leukemia"},{"key":"2025082608315833100_bib29","author":"Deininger","year":"31   4  2024"},{"key":"2025082608315833100_bib30","volume-title":"Iclusig. Prescribing information","year":"2024"},{"key":"2025082608315833100_bib31","volume-title":"Scemblix. Prescribing information","year":"2021"},{"key":"2025082608315833100_bib32","author":"Bosulif","year":"2020"},{"issue":"5","key":"2025082608315833100_bib33","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"2025082608315833100_bib34","author":"Hughes","year":"10-13  2022"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/16\/4248\/2407263\/blooda_adv-2025-016042-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/16\/4248\/2407263\/blooda_adv-2025-016042-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T12:32:05Z","timestamp":1756211525000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/16\/4248\/537146\/Asciminib-remained-superior-vs-bosutinib-in-late"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":34,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,8,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016042","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,26]]},"published":{"date-parts":[[2025,8,15]]}}}